Apoptotic and anti-apoptotic signaling pathways induced by photodynamic therapy with hypericin

Advances in Enzyme Regulation

Volumn 40, Issue 1, 2000, Pages 157-182

  Agostinis, Patrizia ^a   Assefa, Zerihun ^a   Vantieghem, Annelies ^a   Vandenheede, Jackie R ^a   Merlevede, Wilfried ^a   De Witte, Peter ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME C OXIDASE; DRUG DERIVATIVE; HYPERICIN; MITOGEN ACTIVATED PROTEIN KINASE; PERYLENE; STRESS ACTIVATED PROTEIN KINASE; SYNAPTOPHYSIN;

ANIMAL; APOPTOSIS; CELL DEATH; CELL SURVIVAL; CONFERENCE PAPER; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFECT; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME RELEASE; HUMAN; HUMAN CELL; PHOTOCHEMOTHERAPY; PHOTODYNAMIC THERAPY; SIGNAL TRANSDUCTION;

ANIMALIA;

EID: 0034093844     PISSN: 00652571     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0065-2571(99)00021-7     Document Type: Conference Paper

References (71)

1. A. J. HALE, C. A. SMITH, L. C. SUTHERLAND, V. E. A. STONEMAN, V. L. LONGTHORNE, A. C. CULHANE and G. T. WILLIAMS, Apoptosis: molecular regulation of cell death, Eur. J. Biochem. 236, 1-26 (1996).
2. J. F. R. KERR, A. H. WILLIE and A. R. CURRIE, Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics, Brit. J. Cancer 26, 239-257 (1972).
3. L. M. BUJA, M. L. EIGENBRODT and E. H. EIGENBRODT, Apoptosis and necrosis. Basic types and mechanisms of cell death, Arch. Pathol. Lab. Med. 177, 1208-1214 (1993).
4. M. D. JACOBSON, M. WEIL and M. C. RAFF, Programmed cell death in animal development, Cell 88, 347-354 (1997).
5. D. W. NICHOLSON, ICE/CED3-like proteases as therapeutic targets for the control of inappropriate apoptosis, Nature Biotech. 14, 297-301 (1996).
6. C. B. THOMPSON, Apoptosis in the pathogenesis and treatment of disease, Science 267, 1456-1462 (1995).
7. H. PAN, C. YIN VAN and T. DYKE, Apoptosis and cancer mechanisms, Cancer Surveys 29, 305-327 (1997).
8. J. C. REED, T. MIYASHITA, S. TAKAYAMA, H. G. WANG, T. SATO, S. KRAJEWSKI, C. AIME-SEMPE, S. BODRUG, S. KITADA and M. HANADA, BLC-2 family proteins: regulators of cell death involved in the pathogenesis of cancer and resistance to therapy, J. Cell Biochem. 60, 23-32 (1996).
9. G. M. COHEN, Caspases: the executioners of apoptosis, Biochem. J. 326, 1-16 (1997).
10. H. R. STENNICKE and G. S. SALVESEN, Properties of the caspases, Biochim. Biophys. Acta 1387, 17-31 (1998).
11. A. ASHKENAZI and V. M. DIXIT, Death receptor: signaling and modulation, Science 281, 1305-1308 (1998).
12. S. A. SUSIN, N. ZAMZAMI and G. KROEMER, Mitochondria as regulator of apoptosis: doubt no more, Biochim. Biophys. Acta 1366, 151-165 (1998).
13. H. LI, H. ZHU, C. J. XU and J. JUAN, Cleavage of BID by caspase-8 mediates the mitochondrial damage in the Fas pathway of apoptosis, Cell 94, 491-501 (1998).
14. T. S. LEWIS, P. S. SHAPIRO and N. G. AHN, Signal transduction through MAP kinase cascades, Adv. Cancer Res. 74, 49-139 (1998).
15. N. L. JOHNSON, A. M. GARDNER, K. M. DIENER, C. A. LANGE-CARTER, J. GLEAVY, M. B. JARPE, A. MINDEN, M. KARIN, L. I. ZON and G. L. JOHNSON, Signal transduction pathways regulated by mitogen-activated/extracellular response kinase kinase kinase induce cell death, J. Biol. Chem. 271, 3229-3237 (1996).
16. S. HUANG, Y. JIANG, Z. LI, E. NISHIDA, P. MATHIAS, S. LIN, R. J. ULEVITCH, G. R. NEMEROW and J. HAN, Apoptosis signaling pathway in T cells is composed of ICE/Ced-3 family proteases and MAP kinase kinase 6b, Immunity 6, 739-749 (1997).
17. Z. XIA, M. DICKENS, J. RAINGEAUD, R. J. DAVIS and M. E. GREENBERG, Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis, Science 270, 1326-1331 (1995).
18. M. DICKENS, J. S. ROGERS, J. CAVANAGH, A. RAITANO, Z. XIA, GREENBERG M.E. HALPERN JR, C. L. SAWYERS and R. J. DAVIS, A cytoplasmic inhibitor of the JNK signal transduction pathway, Science 277, 693-696 (1997).
19. M. VERHEIJ, R. BOSE, X. H. LIN, B. YAO, W. D. JARVIS, S. GRANT, M. J. BIRRER, E. SZABO, L. I. ZON, J. M. KYRIAKIS, A. HAIMOVITZ-FRIEDMAN, Z. FUKS and R. N. KOLESNICK, Requirement by ceramide-initiated SAPK/JNK signalling in stress-induced apoptosis, Nature 380, 75-79 (1996).
20. Y-R. CHEN, X. WANG, D. TEMPLETON, R. J. DAVIS and T-H. TAN, The role of c-Jun N-terminal kinase (JNK) in apoptosis induced by ultraviolet C and gamma radiation. Duration of JNK activation may determine cell death and proliferation, J. Biol. Chem. 271, 31929-31936 (1996).
21. 2-terminal protein kinase pathway in the cellular response to adriamycin and other chemotherapeutic drugs, J. Biol. Chem. 271, 30950-30955 (1996).
22. X. YANG, R. KHOSRAVI-FAR, H. Y. CHANG and D. BALTIMORE, Daxx, a novel Fas-binding protein that activates JNK and apoptosis, Cell 89, 1067-1076 (1997).
23. Z-G. LIU, H. HSU, D. V. GOEDDEL and M. KARIN, Dissection of the TNF receptor 1 effector functions: JNK activation is not linked to apoptosis while NF-kappaB activation prevents cell death, Cell 87, 565-576 (1996).
24. J. M. LENCZOWSKI, Z. DOMINGUEZ, A. M. EDER, L. B. KING, C. M. ZACHARCHUK and J. D. ASHWELL, Lack of a role for Jun kinase and AP-1 in Fas-induced apoptosis, Mol. Cell Biol. 17, 170-181 (1997).
25. A. KHWAJA and J. DOWNWARD, Lack of correlation between activation of Jun-NH2-terminal kinase and induction of apoptosis after detachment of epithelial cells, J. Cell Biol. 139, 1017-1023 (1997).
26. H. NISHINA, K. D. FISCHER, L. RADVANYI, A. SHAHINIAN, R. HAKEM, E. A. RUBIE, A. BERNSTEIN, T. W. MAK, J. R. WOODGETT and J. M. PENNINGER, Stress-signalling kinase Sek1 protects thymocytes from apoptosis mediated by CD95 and CD3, Nature 385, 350-353 (1997).
27. C. KUHN, S. A. HURWITZ, M. G. KUMAR, J. COTTON and D. F. SPANDAU, Activation of the insulin-like growth factor-1 receptor promotes the survival of human keratinocytes following ultraviolet B irradiation, Int. J. Cancer 80, 431-438 (1999).
28. T. J. DOUGHERTY, C. J. GOMER, B. W. HENDERSON, G. JORI, D. KESSEL, M. KORBELIK, J. MOAN and Q. PENG, Photodynamic therapy, J. Natl. Cancer Inst. 90, 889-905 (1998).
29. S. M. HAHN and E. GLATSTEIN, The emergence of photodynamic therapy as major modality in cancer treatment, Rev. Contemp. Pharmacother. 10, 69-74 (1999).
30. B. EHRENBERG, J. L. ANDERSON and C. S. FOOTE, Kinetics and yield of singlet oxygen photosensitized by hypericin in organic and biological media, Photochem. Photobiol. 68, 135-140 (1998).
31. I. TAKAHASHI, S. NAKANISHI, E. KOBAYASHI, H. NAKANO, K. SUZUKI and T. TAMAOKI, Hypericin and pseudohypericin specifically inhibit protein kinase C: possible relation to their antiretroviral activity, Biochem. Biophys. Res. Commun. 165, 1207-1212 (1989).
32. P. AGOSTINIS, A. VANDENBOGAERDE, A. DONELLA-DEANA, L. A. PINNA, K. LEE, J. GORIS, W. MERLEVEDE, J. R. VANDENHEEDE and P. DE WITTE, Photosensitized inhibition of growth-factor regulated protein kinases by hypericin, Biochem. Pharmacol. 49, 1615-1622 (1995).
33. D. MERUELO, G. LAVIE and D. LAVIE, Therapeutic agents with dramatic antiretroviral activity and little toxicity at effective doses: aromatic polycyclic diones hypericin and pseudohypericin, Proc. Natl. Acad. Sci., USA 85, 5230-5234 (1988).
34. S. N. OKPANYI, B. C. SCHOLL and H. G. MILTENBURGER, Genotoxizitat eines standardisierten Hypericum-Extraktes, Amzneim-Forsch 40, 851-855 (1990).
35. S. DEGAR, A. M. PRINCE, D. PASCUAL, G. LAVIE, B. LEVIN, Y. MAZUR, D. LAVIE, L. S. EHRLICH, C. CARTER and D. MERUELO, Inactivation of the human immunodeficiency virus by hypericin: evidence for photochemical alterations of p24 and a block in uncoating, AIDS Res. Hum. Retroviruses 8, 1929-1936 (1992).
36. J. LENARD, A. RABSON and R. VANDEROEF, Photodynamic inactivation of infectivity of human immunodeficiency virus and other enveloped viruses using hypericin and rose bengal: inhibition of fusion and syncytia formation, Proc. Natl. Acad. Sci., USA 90, 158-162 (1993).
37. J. B. HUDSON, I. LOPEZ-BAZZOCCHI and G. H. N. TOWERS, Antiviral activities of hypericin, Antiviral Res. 15, 101-112 (1991).
38. Z. DIWU and J. W. LOWN, Phototherapeutic potential of alternative photosensitizers to porphyrins, Pharmacol. Ther. 63, 1-35 (1994).
39. C. THOMAS, R. S. MACGILL, P. NEILL and R. S. PARDINI, The in vitro and in vivo photoinduced antineoplastic activity of hypericin, Proc. Amer. Assoc. Cancer Res. 33, 5001 (1992).
40. Z. DIWU, Novel therapeutic and diagnostic applications of hypocrellins and hypericins, Photochem. Photobiol. 6, 529-539 (1995).
41. A. L. VANDENBOGAERDE, K. R. GEBOES, J. F. CUVEELE, P. M. AGOSTINIS, W. J. MERLEVEDE and P. A. DE WITTE, Antitumour activity of photosensitized hypericin on A431 cell xenografts, Anticancer Res. 16, 1611-1618 (1996).
42. M. ALECU, C. URSACIUC, F. HALALAU, G. COMAN, W. MERLEVEDE, E. WAELKENS and P. DE WITTE, Treatment of squamous and basal cell carcinoma with hypericin as a new photodynamic agent, Anticancer Res. 18, 4651-4654 (1998).
43. W. ZHANG, L. ANKER, R. E. LAW, D. R. HINTON, R. GOPALAKRISHNA, W. PU, U. GUNDIMEDA, M. WEISS and W. T. COULDWELL, Enhancement of radiosensitivity in human malignant glioma cells by hypericin in vitro, Clin. Cancer Res. 2, 843-846 (1996).
44. M. S. HARRIS, T. SAKAMOTO, H. KIMURA, S. HE, C. SPEE, R. GOPALAKRISHNA, U. GUNDIMEDA, J. S. YOO, D. R. HINTON and S. J. RYAN, Hypericin inhibits cell growth and induces apoptosis in retinal pigment epithelial cells: possible involvement of protein kinase, C. Curr. Eye Res. 15, 255-262 (1996).
45. Z. ASSEFA, A. VANTIEGHEM, W. DECLERCQ, P. VANDENABEELE, W. VANDENHEEDE JR, MERLEVEDE, P. DE WITTE and P. AGOSTINIS, The activation of the c-Jun N-terminal kinase and p38 mitogen-activated protein kinase signaling pathways protects HeLa cells from apoptosis following photodynamic therapy with hypericin, J. Biol. Chem. 274, 8788-8796 (1999).
46. A. VANTIEGHEM, Z. ASSEFA, P. VANDENABEELE, W. DECLERCQ, S. COURTOIS, W. VANDENHEEDE JR, MERLEVEDE, P. DE WITTE and P. AGOSTINIS, Hypericin-induced photosensitization of HeLa cells leads to apoptosis or necrosis. Involvement of cytochrome C and procaspase-3 activation in the mechanism of apoptosis, FEBS Lett. 440, 19-24 (1998).
47. D. KESSEL and Y. LUO, Mitochondrial photodamage and PDT-induced apoptosis, J. Photochem. Photobiol. B: Biol. 42, 89-95 (1998).
48. B. B. NOODT, G. H. RODAL, M. WAINWRIGHT, Q. PENG, R. HOROBIN, J. M. NESLAND and K. BERG, Apoptosis induction by different pathways with methylene blue derivative and light from mitochondrial sites in V79 cells, Int. J. Cancer 75, 941-948 (1998).
49. A. L. VANDENBOGAERDE, E. DELAEY, A. VANTIEGHEM, B. E. HIMPENS, W. J. MERLEVEDE and P. A. DE WITTE, Cytotoxicity and antiproliferative effect of hypericin and derivatives after photosensitization, Photochem. Photobiol. 67, 119-125 (1998).
50. A. L. VANDENBOGAERDE, P. PROOT, B. E. HIMPENS, W. J. MERLEVEDE and P. A. DE WITTE, Differential cytotoxic effects induced after photosensitization by hypericin, J. Photochem. Photobiol. B. 38, 136-142 (1997).
51. ® photosensitization: influence of the incubation protocol, Photochem. Photobiol. 64, 182-187 (1996).
52. Y. LUO and D. KESSEL, Initiation of apoptosis vs necrosis by photodynamic therapy with chloroaluminum phthalocyanine, Photochem. Photobiol. 66, 479-483 (1997).
53. S. H. KAUFMANN, S. DESNOYERS, Y. OTTAVIANO, N. E. DAVIDSON and G. G. POIRIER, Specific proteolytic cleavage of poly(ADP-ribose) polymerase; an early marker of chemotherapy-induced apoptosis, Cancer Res. 53, 3976-3985 (1993).
54. J. C. HE, C. M. WHITACRE, L. XUE, N. A. BERGER and N. L. OLEINICK, Protease activation and cleavage of poly(ADP-ribose) polymerase: an integral part of apoptosis in response to photodynamic therapy, Cancer Res. 58, 940-946 (1998).
55. J. C. REED, Cytochrome c: can't live with it - can't live without it, Cell 91, 559-562 (1997).
56. 6 mouse mammary carcinoma cells, Free Radical Biol. Med. 25, 144-152 (1998).
57. Y. EGUCHI, S. SHIMIZU and Y. TSUJIMOTO, Intracellular ATP levels determine cell death fate by apoptosis or necrosis, Cancer Res. 57, 1835-1840 (1997).
58. D. J. GRANVILLE, J. G. LEVY and D. W. C. HUNG, Photodynamic therapy induces caspase-3 activation in HL-60 cells, Cell Death Differ. 4, 623-628 (1997).
59. D. J. GRANVILLE, C. M. CARTHY, H. JIANG, G. C. SHORE, B. M. MCMANUS and D. W. HUNT, Rapid cytochrome c release, activation of caspases 3, 6, 7 and 8 followed by Bap31 cleavage in HeLa cells treated with photodynamic therapy, FEBS Lett. 437, 5-10 (1998).
60. J. TAO, J. S. SANGHERA, S. L. PELECH, G. WONG and J. G. LEVY, Stimulation of stress-activated protein kinase and p38 HOG1 kinase in murine keratinocytes following photodynamic therapy with benzoporphyrin derivative, J. Biol. Chem. 271, 27107-27115 (1996).
61. L. O. KLOTZ, C. FRITSCH, K. BRIVIBA, N. TSACMACIDIS, F. SCHLIESS and H. SIES, Activation of JNK and p38 but not ERK MAP kinase in human skin cells by 5-aminolevulinate photodynamic therapy, Cancer Res. 58, 4297-4300 (1998).
62. M. H. CARDONE, G. S. SALVESEN, C. WIDMANN, G. JOHNSON and S. M. FRISCH, The regulation of anoikis: MEKK-1 activation requires cleavage by caspases, Cell 90, 315-323 (1997).
63. M. A. CAHILL, M. E. PETER, F. C. KISCHKEL, A. M. CHINNAIYAN, V. M. DIXIT, P. H. KRAMMER and A. NORDHEIM, CD95 (APO-1/Fas) induces activation of SAP kinases downstream of ICE-like proteases, Oncogene 13, 2087-2096 (1996).
64. P. JUO, C. J. KUO, S. E. REYNOLDS, R. F. KONZ, J. RAINGEAUD, R. J. DAVIS, H-M. BIEMANN and J. BLENIS, Fas activation of the p38 mitogen-activated protein kinase signalling pathway requires ICE/CED-3 family proteases, Mol. Cell Biol. 17, 24-35 (1997).
65. F. MUHLENBECK, E. HAAS, R. SCHWENZER, G. SCHUBERT, M. GRELL, C. SMITH, P. SCHEURICH and H. WAJANT, Trail/Apo2L activates c-Jun NH2-terminal kinase (JNK) via caspase-dependent and caspase-independent pathways, J. Biol. Chem. 273, 33091-33098 (1998).
66. S. M. FRISCH, K. VUORI, D. KELAITA and S. SICKS, A role for Jun-N-terminal kinase in anoikis; suppression by bcl-2 and crmA, J. Cell Biol. 135, 1377-1382 (1996).
67. C. C. FRANKLIN and A. S. KRAFT, Conditional expression of the mitogen-activated protein kinase (MAPK) phosphatase MKP-1 preferentially inhibits p38 MAPK and stress-activated protein kinase in U937 cells, J. Biol. Chem. 272, 16917-16923 (1997).
68. R. ALANI, P. BROWN, B. BINETRUY, H. DOSAKA, R. K. ROSENBERG, P. ANGEL, M. KARIN and M. J. BIRRER, The transactivating domain of the c-Jun proto-oncoprotein is required for cotransformation of rat embryo cells, Mol. Cell Biol. 11, 6286-6295 (1991).
69. A. ROULSTON, C. REINHARD, P. AMIRI and L. T. WILLIAMS, Early activation of c-Jun N-terminal kinase and p38 kinase regulate cell survival in response to tumor necrosis factor alpha, J. Biol. Chem. 273, 10232-10239 (1998).
70. S. Y. LEE, A. REICHLIN, A. SANTANA, K. A. SOKOL, M. C. NUSSENZWEIG and Y. CHOI, TRAF2 is essential for JNK but not NFKB activation and regulates lymphocyte proliferation and survival, Immunity 7, 703-713 (1997).
71. W-C. YEH, A. SHAHINIAN, D. SPEISER, J. KRAUNUS, F. BILLIA, A. WAKEHAM, J. L. DE LA POMPA, D. FERRICK, B. HUM, N. ISCOVE, P. OHASHI, M. ROTHE, D. V. GOEDDEL and T. W. MAK, Early lethality, functional NFKB activation, and increased sensitivity to TNF-induced cell death in TRAF2-deficient mice, Immunity 7, 715-725 (1997).